AzurRx (AZRX) Corporate Media Kit

31 1/3 of all CF patients on PERT achieve less than 80% CFA Majority of severe EPI patients are at maximum (tolerated or recommended) daily PERT dose Risk of fibrosing colonopathy at high daily PERT doses Adding MS1819 to daily PERT may get patients to CFA goal Efficacy endpoint of increasing CFA above 80% in patients with severe EPI Phase 2 Combination Therapy Trial in CF Patients with Severe EPI Substantial unmet need in patients not to goal on chronic PERT therapy